Pazopanib, an anti-angiogenic agent, that blocks multiple driver RTKs including c-Kit, VEGFR, PDGFR as well as kinases from FGFR family, was recently approved for the treatment of soft-tissue sarcoma [28, 44]. Here, KIT is linked to soft tissue sarcoma.